KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

QuidelOrtho (QDEL) Shares Repurchased (2021 - 2023)

QuidelOrtho recorded quarterly Shares Repurchased of -$67.1 million in Q4 2023, down 129.79% quarter-over-quarter from -$29.2 million in Q1 2023, and down 129.79% year-over-year from $225.2 million in Q4 2022.

QuidelOrtho's Shares Repurchased history runs 3 years deep, the most recent figure standing at -$67.1 million for Q4 2023.

  • In Q4 2023, Shares Repurchased fell 129.79% year-over-year to -$67.1 million; the TTM figure through Dec 2023 stood at -$21.9 million (changed N/A YoY), while the FY2023 annual figure was $7.2 million, down 90.31% from the prior year.
  • Shares Repurchased came in at -$67.1 million for Q4 2023 at QuidelOrtho, down from -$29.2 million in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $74.3 million in Q4 2022 to a low of -$67.1 million in Q4 2023.
  • A 3-year average of -$5.5 million and a median of -$14.6 million in 2021 frame the typical range for Shares Repurchased.
  • Across the five-year window, Shares Repurchased soared 74200.0% in 2022 and slumped 129.79% in 2023, its largest moves.
  • QuidelOrtho's Shares Repurchased stood at $100000.0 in 2021, then jumped by 74200.0% to $74.3 million in 2022, then tumbled by 190.31% to -$67.1 million in 2023.
  • According to Business Quant data, Shares Repurchased over the past three periods registered -$67.1 million, -$29.2 million, and $74.3 million for Q4 2023, Q1 2023, and Q4 2022 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 180.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 105.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 421.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 100.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 74.30 Mn
10 QuidelOrtho 898.19 Mn 757.79 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 -67.10 Mn
Dec 31, 2023 -67.10 Mn
Jan 1, 2023 -29.20 Mn
Jan 1, 2023 -29.20 Mn
Oct 2, 2022 74.30 Mn
Oct 2, 2022 74.30 Mn
Oct 3, 2021 100,000.00
Oct 3, 2021 100,000.00